IBM, Merck, Walmart, KPMG and the FDA test Blockchain for traceability of pharmaceutical products.
The FDA pilot program explores innovative and emerging approaches to the tracking and verification of prescription products.
IBM, KPMG, Merck and Walmart have been selected by the United States Food and Drug Administration (FDA) to be included in a program in support of the United States Drug Supply Chain Safety Act (DSCSA) that addresses the requirements to identify, track and trace prescription drugs and vaccines distributed within the United States.
Our strategy, planning, and logistics of the supply chain are based on the clients and patients we serve. Reliable and verifiable supply helps improve trust among all stakeholders, especially patients while strengthening the foundation of our business.
Each company brings a unique experience to the project, which will create a Blockchain network with shared permission that allows the monitoring in real time of the products. In addition, the proposed network is intended to help reduce the time needed to track the inventory and allow the timely recovery of reliable distribution information and increases the accuracy of data shared among network members. It also helps determine the integrity of the products in the distribution chain, including whether the products are kept at the correct temperature.
Karim Bennis, vice president of Planning and Strategic Implementation, Health and Welfare at Walmart, commented:
With the successful Blockchain pilots in pork, mangoes and leafy green vegetables that provide better traceability, we expect the same success and transparency in the biopharmaceutical supply chain. We believe that we must go beyond offering excellent products that help our customers to live better at low prices every day. Our customers should also know that they can trust us to ensure that the products are safe. This pilot and the requirements of the US Drug Supply Chain Safety Act will help us do just that.
Trust Likewise, Mark Treshock, leader of IBM’s Global Solutions for Blockchain in Health and Life Sciences, added:
Blockchain could provide a new important approach to further improve confidence in the biopharmaceutical supply chain. We believe that this is an ideal use for technology because not only can it provide an audit trail that tracks drugs within the supply chain, but it can track who has shared data and with whom, without revealing the data itself. Blockchain has the potential to transform the way pharmaceutical data is controlled, managed, shared and acted throughout the life history of a drug.
Customers request more detailed information about the products. On this, Arun Ghosh, Leader of KPMG Blockchain, commented:
Blockchain’s innate ability within a private network authorized to provide an ‘immutable record’ makes it a logical tool to implement and help address DSCSA compliance requirements. The ability to take advantage of the existing cloud infrastructure is making the corporate blockchain increasingly affordable and adaptable, helping drug manufacturers, distributors and dispensers meet their patient safety and chain integrity goals. supply.
Finally, the pilot project is scheduled to be completed in the fourth quarter of 2019, and the results are expected to be published in a report of the DSCSA FDA program. At that time, the project participants will evaluate the following steps.
Via IBM News Room